Mumbai : Fifteen years ago much before the boom sparked by antiobesity drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide), a group of scientists at Indian drug maker Zydus Lifesciences had quietly struck early success with an oral GLP-1 agonist (Glucagon-like peptide-1 agonists) coded ZYOG1.
The two GLP-1 drugs are known for their properties to slow stomach emptying and cut food cravings. For Zydus, which was building its pipeline of innovative drugs, it was an audacious goal. Obesity drugs had not made the impact and too many large companies were deep in research for anti-diabetes drugs.
